Last reviewed · How we verify
NCT01950182: SYSUCC-002
Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer
Phase 3 trial testing Endocrine therapy combined with trastuzumab in Breast Cancer in 392 participants. Completed in 31 May 2020.
31 May 2020
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 392 |
| Start date | 16 September 2013 |
| Primary completion | 31 May 2020 |
| Estimated completion | 31 May 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Endocrine therapy combined with trastuzumab — full drug profile →
- Chemotherapy combined with trastuzumab — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 75, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic Luminal B2 breast cancer subtype randomised to treatment with Trastuzumab Combined With Chemotherapy or Endocrine Therapy.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.
Cardoso F, Senkus E, Costa A, Papadopoulos E, et al · · 2018 · cited 790× · PMID 30032243 · DOI 10.1093/annonc/mdy192 -
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
Cardoso F, Costa A, Senkus E, Aapro M, et al · · 2017 · cited 267× · PMID 28177437 · DOI 10.1093/annonc/mdw544 -
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer.
Pegram M, Jackisch C, Johnston SRD. · · 2023 · cited 83× · PMID 37258523 · DOI 10.1038/s41523-023-00533-2 -
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.
Yu S, Liu Q, Han X, Qin S, et al · · 2017 · cited 82× · PMID 29209558 · DOI 10.1186/s40164-017-0091-4 -
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.
Larionov AA. · · 2018 · cited 62× · PMID 29670855 · DOI 10.3389/fonc.2018.00089 -
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).
Hua X, Bi XW, Zhao JL, Shi YX, et al · · 2022 · cited 53× · PMID 34810217 · DOI 10.1158/1078-0432.ccr-21-3435 -
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer.
Pegram M, Pietras R, Dang CT, Murthy R, et al · · 2023 · cited 15× · PMID 37576607 · DOI 10.1177/17588359231187201 -
Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer.
Li X, Huang T. · · 2025 · cited 1× · PMID 40983817 · DOI 10.1007/s12282-025-01779-3
Verify or expand the search:
- PubMed search for NCT01950182
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01950182 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 15 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01950182.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing